Danlou Tablets to Prevent Left Ventricular Remodeling
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
Danlou tablets are Chinese patent medicine which has been approved in China for the treatment
of ischemic heart disease, but the evidence supporting its efficacy on cardiac remodeling
remains unclear. This pilot study was designed to determine whether Danlou tablets reduced
adverse left ventricular (LV) remodeling in patients with acute myocardial infarction (MI).
Patients following acute MI were enrolled and randomly allocated to Danlou tablets (4.5 g
q.d. for 90 days) or placebo, superimposed on standard medications for the treatment of MI.
Major end points were changes in LV volumes and ejection fractions as evaluated by serial
echocardiography in addition to clinical outcomes were also determined.